Chronic Pancreatitis: Diagnosis and Treatment
Am Fam Physician. 2018 Mar 15;97(6):385-393.
Patient information: A handout on pancreatitis is available.
Author disclosure: No relevant financial affiliations.
Chronic pancreatitis is an irreversible and progressive disorder of the pancreas characterized by inflammation, fibrosis, and scarring. Exocrine and endocrine functions are lost, often leading to chronic pain. The etiology is multifactorial, although alcoholism is the most significant risk factor in adults. The average age at diagnosis is 35 to 55 years. If chronic pancreatitis is suspected, contrast-enhanced computed tomography is the best imaging modality for diagnosis. Computed tomography may be inconclusive in early stages of the disease, so other modalities such as magnetic resonance imaging, magnetic resonance cholangiopancreatography, or endoscopic ultrasonography with or without biopsy may be used. Recommended lifestyle modifications include cessation of alcohol and tobacco use and eating small, frequent, low-fat meals. Although narcotics and antidepressants provide the most pain relief, one-half of patients eventually require surgery. Therapeutic endoscopy is indicated to treat symptomatic strictures, stones, and pseudocysts. Decompressive surgical procedures, such as lateral pancreaticojejunostomy, are indicated for large duct disease (pancreatic ductal dilation of 7 mm or more). Resection procedures, such as the Whipple procedure, are indicated for small duct disease or pancreatic head enlargement. The risk of pancreatic cancer is increased in patients with chronic pancreatitis, especially hereditary pancreatitis. Although it is not known if screening improves outcomes, clinicians should counsel patients on this increased risk and evaluate patients with weight loss or jaundice for neoplasm.
Chronic pancreatitis is a permanent, progressive destruction of pancreatic tissue and function. Clinical manifestations include disabling abdominal pain, steatorrhea, and diabetes mellitus.1–3 Incidence and prevalence remain low and, despite advances in medical imaging, definitive diagnosis remains challenging.3 Primary care physicians should be familiar with presenting clinical features, as well as treatment options and long-term complications.
WHAT IS NEW ON THIS TOPIC
A meta-analysis of 43 studies that included more than 3,400 patients concluded that computed tomography, magnetic resonance imaging, endoscopic retrograde cholangiopancreatography, and endoscopic ultrasonography have comparably high diagnostic accuracy for chronic pancreatitis; therefore, a stepwise approach based on cost, invasiveness, and availability is recommended.
A Cochrane review of 10 trials involving 361 participants suggested that pancreatic enzyme replacement does not reduce pain from chronic pancreatitis.
SORT: KEY RECOMMENDATIONS FOR PRACTICE
| Clinical recommendation | Evidence rating | References |
|---|---|---|
Contrast-enhanced computed tomography is the recommended initial imaging study in patients with suspected chronic pancreatitis. | C | |
Endoscopic ultrasonography is favored over endoscopic retrograde cholangiopancreatography for the endoscopic diagnosis of chronic pancreatitis because of its increased safety and ability to evaluate the pancreatic parenchyma and duct system. | C | |
Antioxidant therapy does not improve pain control or mortality outcomes in patients with chronic pancreatitis. | B | |
Pancreatic enzyme replacement is indicated for steatorrhea and malabsorption and may help relieve pain in patients with chronic pancreatitis. | B | |
Endoscopic drainage of pseudocysts results in a similar rate of pain relief as surgery, with equivalent or lower mortality. | B | |
Pancreatoduodenectomy (Whipple procedure, pylorus-preserving, or duodenum-preserving) is indicated in the treatment of chronic pancreatitis with pancreatic head enlargement and typically results in significant pain relief. | B |
A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.
SORT: KEY RECOMMENDATIONS FOR PRACTICE
| Clinical recommendation | Evidence rating | References |
|---|---|---|
Contrast-enhanced computed tomography is the recommended initial imaging study in patients with suspected chronic pancreatitis. | C | |
Endoscopic ultrasonography is favored over endoscopic retrograde cholangiopancreatography for the endoscopic diagnosis of chronic pancreatitis because of its increased safety and ability to evaluate the pancreatic parenchyma and duct system. | C | |
Antioxidant therapy does not improve pain control or mortality outcomes in patients with chronic pancreatitis. | B | |
Pancreatic enzyme replacement is indicated for steatorrhea and malabsorption and may help relieve pain in patients with chronic pancreatitis. | B | |
Endoscopic drainage of pseudocysts results in a similar rate of pain relief as surgery, with equivalent or lower mortality. | B | |
Pancreatoduodenectomy (Whipple procedure, pylorus-preserving, or duodenum-preserving) is indicated in the treatment of chronic pancreatitis with pancreatic head enlargement and typically results in significant pain relief. | B |
A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.
Etiology
Data from case series and cross-sectional studies estimate that the incidence of chronic pancreatitis is between about four and 12 per 100,000 persons per year. Data on prevalence are scarce, with estimates ranging from 37 to 42 per 100,000 persons.3 Men are affected 1.5 to 3 times more than women.4 The average age at diagnosis is 35 to 55 years. Alcoholism is the most significant risk factor for the development of chronic pancreatitis, accounting for 70% of cases in adults. Genetic disease, especially cystic fibrosis, and anatomic abnormalities are the most common causes in children. Table 1 includes the TIGAR-O (toxic-metabolic, idiopathic, genetic, autoimmune, recurrent and severe acute pancreatitis, obstructive) classification of common risk factors for chronic pancreatitis.4,5
TIGAR-O Classification of Risk Factors Associated with Chronic Pancreatitis
Toxic-metabolic |
Alcohol |
Chronic renal failure |
Hypercalcemia (hyperparathyroidism) |
Hyperlipidemia (rare) |
Medications* |
Tobacco |
Toxins |
Idiopathic |
Early and late onset |
Tropical pancreatitis (tropical calcifying pancreatitis and fibrocalculous pancreatic diabetes) |
Genetic |
Autosomal dominant (cationic trypsinogen [codon 29 and 122 mutations]) |
Autosomal recessive modifier genes (CFTR and SPINK1 mutations, cationic trypsinogen [codon 16, 22, and 23 mutations], alpha1-antitrypsin deficiency) |
Autoimmune |
Autoimmune chronic pancreatitis associated with inflammatory bowel disease, Sjögren syndrome, primary biliary cirrhosis |
Isolated autoimmune chronic pancreatitis |
Recurrent and severe acute pancreatitis |
Postirradiation |
Postnecrotic (severe acute pancreatitis) |
Recurrent acute pancreatitis |
Vascular ischemia |
Obstructive |
Duct obstruction (pancreatic or ampullary tumors) posttraumatic pancreatic duct fibrosis) |
Pancreas divisum |
Sphincter of Oddi disorders |
*—Drug-induced pancreatitis is mostly acute or recurrent acute pancreatitis, specifically in high-risk populations (e.g., older persons; patients with human immunodeficiency virus infection, cancer, or other immunocompromising condition). Common drugs that may induce chronic pancreatitis include angiotensin-converting enzyme inhibitors, statins, didanosine (Videx), azathioprine (Imuran), steroids, lamivudine (Epivir), hydrochlorothiazide, valproic acid (Depakene), oral contraceptives, and interferon.
Adapted with permission from Etemad B, Whitcomb DC. Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology. 2001;120(3):691, with additional information from reference 5.
TIGAR-O Classification of Risk Factors Associated with Chronic Pancreatitis
Toxic-metabolic |
Alcohol |
Chronic renal failure |
Hypercalcemia (hyperparathyroidism) |
Hyperlipidemia (rare) |
Medications* |
Tobacco |
Toxins |
Idiopathic |
Early and late onset |
Tropical pancreatitis (tropical calcifying pancreatitis and fibrocalculous pancreatic diabetes) |
Genetic |
Autosomal dominant (cationic trypsinogen [codon 29 and 122 mutations]) |
Autosomal recessive modifier genes (CFTR and SPINK1 mutations, cationic trypsinogen [codon 16, 22, and 23 mutations], alpha1-antitrypsin deficiency) |
Autoimmune |
Autoimmune chronic pancreatitis associated with inflammatory bowel disease, Sjögren syndrome, primary biliary cirrhosis |
Isolated autoimmune chronic pancreatitis |
Recurrent and severe acute pancreatitis |
Postirradiation |
Postnecrotic (severe acute pancreatitis) |
Recurrent acute pancreatitis |
Vascular ischemia |
Obstructive |
Duct obstruction (pancreatic or ampullary tumors) posttraumatic pancreatic duct fibrosis) |
Pancreas divisum |
Sphincter of Oddi disorders |
*—Drug-induced pancreatitis is mostly acute or recurrent acute pancreatitis, specifically in high-risk populations (e.g., older persons; patients with human immunodeficiency virus infection, cancer, or other immunocompromising condition). Common drugs that may induce chronic pancreatitis include angiotensin-converting enzyme inhibitors, statins, didanosine (Videx), azathioprine (Imuran), steroids, lamivudine (Epivir), hydrochlorothiazide, valproic acid (Depakene), oral contraceptives, and interferon.
Adapted with permission from Etemad B, Whitcomb DC. Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology. 2001;120(3):691, with additional information from reference 5.
Pathophysiology
The pathophysiology of chronic pancreatitis involves progressive fibrotic destruction of the pancreas in response to inflammation. A simple model involving the “two-hit” theory has been proposed. The first hit is acute pancreatitis, causing injury to the pancreas. The second hit is an abnormal inflammatory response to this injury. This causes sustained activation of pancreatic profibrotic cells, including stellate cells. In at-risk individuals, this can result in collagen deposition and fibrosis, which can lead to chronic pancreatitis.2–4,6–8 However, a subset of chronic pancreatitis is caused by autoimmune and genetic factors. Chronic pancreatitis is autoimmune in 5% to 6% of cases.9 Autoimmune pancreatitis has a distinctive histologic appearance with lymphocytic infiltration, but also results in fibrosis and loss of pancreatic function.3
Diagnosis of Chronic Pancreatitis
CLINICAL PRESENTATION
Patients most commonly present with recurrent episodes of acute pancreatitis. This will often progress to chronic abdominal pain that is characteristically located in the epigastrium and radiates to the back. The pain is worsened by eating and relieved by leaning forward. In time, it may spontaneously resolve as the pancreas fails.2,10–12 Although most patients present with pain, pancreatitis is painless in roughly 10% to 20% of patients.1 When about 90% of pancreatic function is lost, patients will have signs of exocrine dysfunction, such as steatorrhea, malabsorption, and fat-soluble vitamin deficiencies (A, D, E, K, B12).1,10,13,14 Endocrine dysfunction, such as diabetes, will also develop.1,13
DIFFERENTIAL DIAGNOSIS
Table 2 includes a comprehensive differential diagnosis.15 Amylase and lipase levels may be elevated in patients with chronic pancreatitis, but these elevations may occur with other conditions that also present with abdominal pain, such as mesenteric ischemia, biliary disease, renal disease, and complicated peptic ulcer disease.2,13,16–18
Differential Diagnosis of Chronic Pancreatitis
| More common | Less common |
|---|---|
Acute cholecystitis | Acute appendicitis |
Acute pancreatitis | Acute salpingitis |
Intestinal ischemia or infarction | Crohn disease |
Obstruction of common bile duct | Ectopic pregnancy |
Pancreatic tumors | Gastroparesis |
Peptic ulcer disease | Intestinal obstruction |
Renal insufficiency | Irritable bowel syndrome |
Malabsorption | |
Ovarian cyst | |
Papillary cystadenocarcinoma of the ovary | |
Thoracic radiculopathy |
Adapted with permission from Nair RJ, Lawler L, Miller MR. Chronic pancreatitis. Am Fam Physician. 2007;76(11):1681.
Differential Diagnosis of Chronic Pancreatitis
| More common | Less common |
|---|---|
Acute cholecystitis | Acute appendicitis |
Acute pancreatitis | Acute salpingitis |
Intestinal ischemia or infarction | Crohn disease |
Obstruction of common bile duct | Ectopic pregnancy |
Pancreatic tumors | Gastroparesis |
Peptic ulcer disease | Intestinal obstruction |
Renal insufficiency | Irritable bowel syndrome |
Malabsorption | |
Ovarian cyst | |
Papillary cystadenocarcinoma of the ovary | |
Thoracic radiculopathy |
Adapted with permission from Nair RJ, Lawler L, Miller MR. Chronic pancreatitis. Am Fam Physician. 2007;76(11):1681.
DIAGNOSTIC TESTING
The diagnosis of chronic pancreatitis is made based on a patient's history, clinical presentation, and imaging findings. There is no single test that is diagnostic of chronic pancreatitis, especially in the early stages. If chronic pancreatitis is suspected based on history and physical examination, a diagnostic workup should be initiated. Diagnostic tests should be chosen based on their availability after consideration of risks and benefits.1,2,4,9,18–20 Laboratory tests used in the evaluation of patients with suspected chronic pancreatitis are summarized in Table 3.15
Laboratory Tests Used in the Evaluation of Patients with Suspected Chronic Pancreatitis
| Tests | Comments | |
|---|---|---|
Complete blood count | Elevated with infection, abscess | |
Serum amylase and lipase | Nonspecific for chronic pancreatitis | |
Total bilirubin, alkaline phosphatase, and hepatic transaminase | Elevated in biliary pancreatitis and ductal obstruction by strictures or mass | |
Fasting serum glucose | Elevation suggests pancreatic diabetes mellitus | |
Pancreatic function tests | Sometimes useful in early chronic pancreatitis with normal computed tomography or magnetic resonance imaging findings | |
Fecal elastase | < 200 mcg per g of stool is abnormal; noninvasive, exogenous pancreatic supplementation will not alter results, requires only 20 g of stool | |
Fecal fat estimation | > 7 g of fat per day is abnormal; quantitative, requires 72 hours, should be on a diet of 100 g of fat per day | |
Secretin stimulation | Peak bicarbonate concentration < 80 mEq per L (80 mmol per L) in duodenal secretion, best test for diagnosing pancreatic exocrine insufficiency | |
Serum trypsinogen | < 20 ng per mL is abnormal | |
Lipid panel | Significantly elevated triglycerides are a rare cause of chronic pancreatitis | |
Calcium | Hyperparathyroidism is a rare cause of chronic pancreatitis | |
Immunoglobulin G4 serum antibody, antinuclear antibody, rheumatoid factor, erythrocyte sedimentation rate | Abnormality may indicate autoimmune pancreatitis | |
Note: Tests are listed in order of most to least commonly performed.
Adapted with permission from Nair RJ, Lawler L, Miller MR. Chronic pancreatitis. Am Fam Physician. 2007; 76(11):1681.
Laboratory Tests Used in the Evaluation of Patients with Suspected Chronic Pancreatitis
| Tests | Comments | |
|---|---|---|
Complete blood count | Elevated with infection, abscess | |
Serum amylase and lipase | Nonspecific for chronic pancreatitis | |
Total bilirubin, alkaline phosphatase, and hepatic transaminase | Elevated in biliary pancreatitis and ductal obstruction by strictures or mass | |
Fasting serum glucose | Elevation suggests pancreatic diabetes mellitus | |
Pancreatic function tests | Sometimes useful in early chronic pancreatitis with normal computed tomography or magnetic resonance imaging findings | |
Fecal elastase | < 200 mcg per g of stool is abnormal; noninvasive, exogenous pancreatic supplementation will not alter results, requires only 20 g of stool | |
Fecal fat estimation | > 7 g of fat per day is abnormal; quantitative, requires 72 hours, should be on a diet of 100 g of fat per day | |
Secretin stimulation | Peak bicarbonate concentration < 80 mEq per L (80 mmol per L) in duodenal secretion, best test for diagnosing pancreatic exocrine insufficiency | |
Serum trypsinogen | < 20 ng per mL is abnormal | |
Lipid panel | Significantly elevated triglycerides are a rare cause of chronic pancreatitis | |
Calcium | Hyperparathyroidism is a rare cause of chronic pancreatitis | |
Immunoglobulin G4 serum antibody, antinuclear antibody, rheumatoid factor, erythrocyte sedimentation rate | Abnormality may indicate autoimmune pancreatitis | |
Note: Tests are listed in order of most to least commonly performed.
Adapted with permission from Nair RJ, Lawler L, Miller MR. Chronic pancreatitis. Am Fam Physician. 2007; 76(11):1681.
Laboratory Testing. In acute pancreatitis, pancreatic enzymes are elevated more than three times the upper limit of normal.16,18 In chronic pancreatitis, these enzymes may be only mildly elevated or normal, especially as the pancreas is replaced by increasing amounts of fibrotic tissue later in the disease process.1 If the biliary tract is obstructed (5% to 10% of cases), bilirubin, alkaline phosphatase, and hepatic transaminases may be elevated.1,16
Pancreatic function tests use a catheter inserted into the pancreatic duct to directly measure pancreatic enzyme secretion. These tests are expensive and challenging to perform. The positive predictive value of these tests is just 45%, but the negative predictive value is 97%. Therefore, although they are not recommended as part of the routine workup, they can be useful for ruling out chronic pancreatitis in patients who exhibit clinical features of pancreatitis but have normal imaging.1,2,4,10,19–21 Fecal elastase is an indirect measure of pancreatic exocrine function that has high sensitivity (65% to 100%) and poor specificity (55%). The high false-positive rate makes this a poor screening test, but it can be helpful in ruling out pancreatitis.19
Imaging Studies. The radiologic evaluation of a patient with suspected chronic pancreatitis should progress from least invasive to more invasive. A meta-analysis of 43 studies that included more than 3,400 patients concluded that computed tomography (CT), magnetic resonance imaging (MRI), endoscopic retrograde cholangiopancreatography, and endoscopic ultrasonography (EUS) have comparably high diagnostic accuracy; therefore, a stepwise approach based on cost, invasiveness, and availability is recommended.22 eTable A includes the sensitivity and specificity of available imaging techniques. Contrast-enhanced CT of the pancreas is the first-choice modality because it is noninvasive and readily available.3 Ductal calcifications are pathognomonic findings of chronic pancreatitis (Figure 115). CT can detect conditions that mimic chronic pancreatitis, as well as complications of chronic pancreatitis, such as pseudocysts, ductal dilation, pseudoaneurysms, necrosis, and parenchymal atrophy.3,10,22–24
Imaging and Endoscopic Studies for Diagnosing Chronic Pancreatitis
| Test | Sensitivity (%) | Specificity (%) | Comment |
|---|---|---|---|
Contrast-enhanced CT | 75 to 90 | 85 to 91 | Initial radiologic test of choice for evaluation of suspected chronic pancreatitis; can visualize calcifications, pseudocysts, thrombosis, pseudoaneurysms, necrosis, and atrophy |
Endoscopic retrograde cholangiopancreatography | 75 to 95 | 90 to 94 | Reference standard in many studies, invasive and associated with complications, mainly used in diagnosis of early chronic pancreatitis with normal CT and pancreatic function tests |
Endoscopic ultrasonography | 81 to 97 | 60 to 90 | Useful in evaluation of early chronic pancreatitis, pancreatic mass, and cystic lesions; can be combined with fine-needle aspiration biopsy |
Magnetic resonance imaging or magnetic resonance cholangiopancreatography | 78 | 96 to 100 | Noninvasive and nonionizing radiation or contrast media, less sensitive than endoscopic retrograde cholangiopancreatography for evaluation of side branches, can be combined with secretin test |
Plain abdominal radiography | NA | NA | Not routinely recommended; calcifications may be visible |
Ultrasonography | 67 | 98 | Rarely diagnostic; may be useful for ultrasonography-guided aspiration of cyst |
CT = computed tomography; NA = not available.
Adapted with permission from Nair RJ, Lawler L, Miller MR. Chronic pancreatitis. Am Fam Physician. 2007;76(11):1683.
Additional information from:
Adler DG, Baron TH, Davila RE, et al.; Standards of Practice Committee of American Society for Gastrointestinal Endoscopy. ASGE guideline: the role of ERCP in diseases of the biliary tract and the pancreas. Gastrointest Endosc. 2005;62(1):1–8.
Issa Y, Kempeneers MA, van Santvoort HC, Bollen TL, Bipat S, Boermeester MA. Diagnostic performance of imaging modalities in chronic pancreatitis: a systematic review and meta-analysis. Eur Radiol. 2017;27(9):3820–3844.
Imaging and Endoscopic Studies for Diagnosing Chronic Pancreatitis
| Test | Sensitivity (%) | Specificity (%) | Comment |
|---|---|---|---|
Contrast-enhanced CT | 75 to 90 | 85 to 91 | Initial radiologic test of choice for evaluation of suspected chronic pancreatitis; can visualize calcifications, pseudocysts, thrombosis, pseudoaneurysms, necrosis, and atrophy |
Endoscopic retrograde cholangiopancreatography | 75 to 95 | 90 to 94 | Reference standard in many studies, invasive and associated with complications, mainly used in diagnosis of early chronic pancreatitis with normal CT and pancreatic function tests |
Endoscopic ultrasonography | 81 to 97 | 60 to 90 | Useful in evaluation of early chronic pancreatitis, pancreatic mass, and cystic lesions; can be combined with fine-needle aspiration biopsy |
Magnetic resonance imaging or magnetic resonance cholangiopancreatography | 78 | 96 to 100 | Noninvasive and nonionizing radiation or contrast media, less sensitive than endoscopic retrograde cholangiopancreatography for evaluation of side branches, can be combined with secretin test |
Plain abdominal radiography | NA | NA | Not routinely recommended; calcifications may be visible |
Ultrasonography | 67 | 98 | Rarely diagnostic; may be useful for ultrasonography-guided aspiration of cyst |
CT = computed tomography; NA = not available.
Adapted with permission from Nair RJ, Lawler L, Miller MR. Chronic pancreatitis. Am Fam Physician. 2007;76(11):1683.
Additional information from:
Adler DG, Baron TH, Davila RE, et al.; Standards of Practice Committee of American Society for Gastrointestinal Endoscopy. ASGE guideline: the role of ERCP in diseases of the biliary tract and the pancreas. Gastrointest Endosc. 2005;62(1):1–8.
Issa Y, Kempeneers MA, van Santvoort HC, Bollen TL, Bipat S, Boermeester MA. Diagnostic performance of imaging modalities in chronic pancreatitis: a systematic review and meta-analysis. Eur Radiol. 2017;27(9):3820–3844.
FIGURE 1.
Contrast-enhanced computed tomography of the upper abdomen showing (A) pancreatic calcifications (arrow) with fluid and edema around the pancreas; and (B) pancreatic calcifications (arrow) with fluid and edema around the head of the pancreas.
Reprinted with permission from Nair RJ, Lawler L, Miller MR. Chronic pancreatitis. Am Fam Physician. 2007;76(11):1682.
FIGURE 1.
Contrast-enhanced computed tomography of the upper abdomen showing (A) pancreatic calcifications (arrow) with fluid and edema around the pancreas; and (B) pancreatic calcifications (arrow) with fluid and edema around the head of the pancreas.
Reprinted with permission from Nair RJ, Lawler L, Miller MR. Chronic pancreatitis. Am Fam Physician. 2007;76(11):1682.
If CT findings are equivocal, patients may require referral for more focused pancreatic imaging, such as MRI or magnetic resonance cholangiopancreatography, or for endoscopic procedures, such as EUS or endoscopic retrograde cholangiopancreatography.3 Magnetic resonance cholangiopancreatography and EUS are useful for evaluating the pancreatic parenchyma and duct system. Endoscopic retrograde cholangiopancreatography has a high risk of complications (e.g., pancreatitis, hemorrhage, infection), so it is not recommended for diagnosis unless all other tests are inconclusive.2,25
APPROACH TO A PATIENT WITH SUSPECTED CHRONIC PANCREATITIS
Figure 2 shows a five-step diagnostic approach to patients with signs and symptoms of chronic pancreatitis. CT will detect involvement of large duct disease (pancreatic ductal dilation of 7 mm or more).2,4,10 CT may be inconclusive in patients with early disease or small duct disease (pancreatic ductal dilation less than 7 mm). These patients should be referred to a center with expertise in pancreatic care for an MRI or magnetic resonance cholangiopancreatography.3 These imaging modalities, with EUS, are also useful for preoperative planning in patients with stones, strictures, or pseudocysts.2–4,23,25–27 If a cystic lesion or mass is identified on imaging, malignancy must be excluded through EUS with biopsy and tumor marker analysis, specifically cancer antigen 19-9.2,3,28,29 If chronic pancreatitis is still suspected despite normal imaging findings, pancreatic function tests can be performed.2–4,27–29 A small study of 25 patients suggests that combining EUS and pancreatic function tests can improve the sensitivity of diagnosis.30
Treatment
Treatment of chronic pancreatitis can be medical, endoscopic, or surgical (Table 4).15 The goals of all treatment modalities are improved pain, improved quality of life, and decreased morbidity and mortality from endocrine and exocrine pancreatic dysfunction. Studies that compare conservative medical therapy with invasive endoscopic or surgical interventions are lacking. Therefore, treatment decisions should be based on careful consideration of the goals of treatment and the risks vs. benefits.31,32
Chronic Pancreatitis Treatment Options
Medical | |
Analgesics (stepwise approach) | |
Antidepressants (treatment of concurrent depression) | |
Cessation of alcohol and tobacco use | |
Denervation (celiac nerve blocks, transthoracic splanchnicectomy) | |
Insulin (for pancreatic diabetes) | |
Low-fat diet and small meals | |
Pancreatic enzymes with proton pump inhibitors or histamine H2 blockers | |
Steroid therapy (in autoimmune pancreatitis) | |
Vitamin supplementation (A, D, E, K, and B12) | |
Endoscopic | |
Extracorporeal shock wave lithotripsy with or without endoscopy | |
Pancreatic sphincterotomy and stent placement for pain relief | |
Transampullary or transgastric drainage of pseudocyst | |
Surgical | |
Decompression | |
Cystenterostomy | |
Lateral pancreaticojejunostomy (most common) | |
Sphincterotomy or sphincteroplasty | |
Resection | |
Distal or total pancreatectomy | |
Pancreatoduodenectomy (Whipple procedure, pylorus-preserving, duodenum-preserving) | |
Not recommended | |
Allopurinol | |
Antioxidant therapy (vitamin C, vitamin E, selenium, methionine [no longer available in the United States]) | |
Octreotide (Sandostatin) | |
Prokinetic agents (erythromycin) | |
Adapted with permission from Nair RJ, Lawler L, Miller MR. Chronic pancreatitis. Am Fam Physician. 2007;76(11):1684.
Chronic Pancreatitis Treatment Options
Medical | |
Analgesics (stepwise approach) | |
Antidepressants (treatment of concurrent depression) | |
Cessation of alcohol and tobacco use | |
Denervation (celiac nerve blocks, transthoracic splanchnicectomy) | |
Insulin (for pancreatic diabetes) | |
Low-fat diet and small meals | |
Pancreatic enzymes with proton pump inhibitors or histamine H2 blockers | |
Steroid therapy (in autoimmune pancreatitis) | |
Vitamin supplementation (A, D, E, K, and B12) | |
Endoscopic | |
Extracorporeal shock wave lithotripsy with or without endoscopy | |
Pancreatic sphincterotomy and stent placement for pain relief | |
Transampullary or transgastric drainage of pseudocyst | |
Surgical | |
Decompression | |
Cystenterostomy | |
Lateral pancreaticojejunostomy (most common) | |
Sphincterotomy or sphincteroplasty | |
Resection | |
Distal or total pancreatectomy | |
Pancreatoduodenectomy (Whipple procedure, pylorus-preserving, duodenum-preserving) | |
Not recommended | |
Allopurinol | |
Antioxidant therapy (vitamin C, vitamin E, selenium, methionine [no longer available in the United States]) | |
Octreotide (Sandostatin) | |
Prokinetic agents (erythromycin) | |
Adapted with permission from Nair RJ, Lawler L, Miller MR. Chronic pancreatitis. Am Fam Physician. 2007;76(11):1684.
MEDICAL
Eliminating alcohol and tobacco use slows disease progression and lessens complications, such as cancer.33 Dietary changes, particularly eating small, frequent, low-fat meals, can also help decrease pain and complications.2,3,10,34
Disabling pain is the most common symptom of chronic pancreatitis. Because treatment with narcotic pain medications can lead to opioid addiction, beginning with nonsteroidal anti-inflammatory drugs or acetaminophen is recommended. Adding narcotic pain medications in a stepwise approach may be necessary to obtain adequate pain control. Adjunctive therapy with tricyclic antidepressants, selective serotonin reuptake inhibitors, and combined serotonin and norepinephrine reuptake inhibitors is used to act in synergy with narcotics and treat concomitant depression that is common in patients with chronic pancreatitis.31,32
A Cochrane review of antioxidant therapy, including selenium, beta carotene, l-methionine, vitamin C, and vitamin E, did not find evidence of effectiveness.35 Other studies found that octreotide (Sandostatin), allopurinol, or vitamin D provided no pain relief.10 In a three-week long study funded by the manufacturer, pregabalin (Lyrica) decreased short-term opioid use and improved short-term pain scores.36,37 However, studies with longer follow-up and larger sample size are needed before this becomes a standard treatment for chronic pancreatitis pain.
Pancreatic enzyme replacement is beneficial for the treatment of steatorrhea and malabsorption.38–41 A Cochrane review of 10 trials involving 361 participants suggested that pancreatic enzyme replacement does not reduce pain from chronic pancreatitis, although results of individual studies were mixed.42
ENDOSCOPY
Endoscopy can be used to treat symptomatic strictures, stones, and pseudocysts. Endoscopic drainage of pseudocysts has a similar rate of pain relief as surgery, with equivalent or lower mortality.25,43–48 Regression of the cyst occurs in 70% to 86% of patients after endoscopic drainage.25–28,43–46 Endoscopic sphincterotomy or stent placement can provide pain relief without the risks of surgery in patients with strictures.10,25,27 Extracorporeal shock wave lithotripsy with or without endoscopic drainage of the pancreatic duct can reduce stone burden and pain.10,25,49,50
SURGERY
One-half of patients with chronic pancreatitis will eventually require surgery,1 most commonly because of intractable, disabling pain.51 Indications for surgery are listed in Table 5.15 There are two types of surgeries for chronic pancreatitis. Decompression procedures are performed on patients with large duct disease, whereas resection procedures are performed on patients with small duct disease or pancreatic head enlargement.
Chronic Pancreatitis: Indications for Surgery
Biliary or pancreatic stricture |
Duodenal stenosis |
Fistulas (peritoneal or pleural effusion) |
Hemorrhage |
Intractable chronic abdominal pain |
Pseudocysts |
Suspected pancreatic neoplasm |
Vascular complications |
Adapted with permission from Nair RJ, Lawler L, Miller MR. Chronic pancreatitis. Am Fam Physician. 2007;76(11):1684.
Chronic Pancreatitis: Indications for Surgery
Biliary or pancreatic stricture |
Duodenal stenosis |
Fistulas (peritoneal or pleural effusion) |
Hemorrhage |
Intractable chronic abdominal pain |
Pseudocysts |
Suspected pancreatic neoplasm |
Vascular complications |
Adapted with permission from Nair RJ, Lawler L, Miller MR. Chronic pancreatitis. Am Fam Physician. 2007;76(11):1684.
The most common decompression procedure is lateral pancreaticojejunostomy (Figure 3A15). This procedure is more effective at providing long-term pain relief (60% to 91% of patients) than endoscopic approaches.2,52–54 Surgery may also be performed to drain a symptomatic pseudocyst; however, because endoscopic approaches are as effective at relieving pain with fewer risks, surgery is reserved for when endoscopic intervention is ineffective or for complicated pseudocysts.47,48
Resection procedures 55,56 include pancreatoduodenectomy (Whipple procedure, Figure 3B15), pylorus-preserving pancreatoduodenectomy (Figure 3C15), duodenum-preserving pancreatic head resection (Beger or Frey procedures), and total pancreatectomy (Figure 3D15). The Whipple procedure is the most commonly performed surgery in patients with chronic pancreatitis because of its high success rate (pain relief in 85% of patients) and low mortality (less than 3%).8,55,56 Pancreatoduodenectomy is indicated with pancreatic head enlargement and typically results in significant pain relief.51 A Cochrane review of five trials including 292 participants compared the Whipple procedure with duodenum-preserving pancreatic head resection. Although hospital stay was shorter for duodenum-preserving pancreatic head resection, there was no statistical difference in mortality or quality of life.57,58 Total pancreatectomy is rarely performed because of high rates of complications and low rates of pain relief. Because of the high risk of diabetes in patients with chronic pancreatitis, total pancreatectomy should always be performed with an autologous islet cell transplant.56,59
FIGURE 3.
Most patients with chronic pancreatitis undergo surgery when initial medical and endoscopic treatments do not relieve pain. Surgical interventions include (A) lateral pancreaticojejunostomy, (B) pancreatoduodenectomy (Whipple procedure), (C) pylorus-preserving pancreatoduodenectomy, and (D) total pancreatectomy.
Illustrations by Dave Klemm.
Reprinted with permission from Nair RJ, Lawler L, Miller MR. Chronic pancreatitis. Am Fam Physician. 2007;76(11):1685.
FIGURE 3.
Most patients with chronic pancreatitis undergo surgery when initial medical and endoscopic treatments do not relieve pain. Surgical interventions include (A) lateral pancreaticojejunostomy, (B) pancreatoduodenectomy (Whipple procedure), (C) pylorus-preserving pancreatoduodenectomy, and (D) total pancreatectomy.
Illustrations by Dave Klemm.
Reprinted with permission from Nair RJ, Lawler L, Miller MR. Chronic pancreatitis. Am Fam Physician. 2007;76(11):1685.
Complications
Complications of chronic pancreatitis are summarized in Table 6.13,15,55,60 The most common causes of morbidity and mortality are chronic debilitating pain, diabetes, pancreatic pseudocysts, and pancreatic cancer. Although pain is often present at diagnosis, it takes roughly five years for diabetes to develop.12,13,55,61 Pancreatic pseudocysts are usually asymptomatic but may cause serious complications in 25% to 30% of patients with pancreatitis. Pseudocysts can lead to rupture, infection, bleeding, and obstruction.10,13,54,55 Recurrent attacks of acute pancreatitis can cause pancreatic abscesses and necrosis, sepsis, and multi-organ failure.18 Almost one-fourth of patients (23.4%) with chronic pancreatitis have osteoporosis and almost two-thirds (65%) have osteoporosis or osteopenia.60 There is a markedly increased risk of pancreatic cancer in patients with chronic pancreatitis, particularly among those with long-term alcohol use or hereditary pancreatitis.2,3,12,14,25–28
Complications of Chronic Pancreatitis
| Complication | Incidence (%) |
|---|---|
Acute pancreatitis | Recurrent |
Chronic pain | 80 to 90 |
Osteoporosis or osteopenia | 65 |
Diabetes mellitus | > 40 |
Weight loss | > 40 |
Pseudocyst | 25 to 30 |
Pancreatic cancer | 15 to 40 |
Malabsorption and steatorrhea | 10 to 15 |
Bile duct, duodenal, or gastric obstruction | 5 to 10 |
Pancreatic ascites or pleural effusion | < 10 |
Pseudoaneurysm, especially of splenic artery | < 1 |
Splenic or portal vein thrombosis | < 1 |
Vitamin deficiency (A, D,* E, K, and B12) | Rare |
Complications of Chronic Pancreatitis
| Complication | Incidence (%) |
|---|---|
Acute pancreatitis | Recurrent |
Chronic pain | 80 to 90 |
Osteoporosis or osteopenia | 65 |
Diabetes mellitus | > 40 |
Weight loss | > 40 |
Pseudocyst | 25 to 30 |
Pancreatic cancer | 15 to 40 |
Malabsorption and steatorrhea | 10 to 15 |
Bile duct, duodenal, or gastric obstruction | 5 to 10 |
Pancreatic ascites or pleural effusion | < 10 |
Pseudoaneurysm, especially of splenic artery | < 1 |
Splenic or portal vein thrombosis | < 1 |
Vitamin deficiency (A, D,* E, K, and B12) | Rare |
Surveillance
Patients with hereditary pancreatitis have a 10-fold increased risk of pancreatic cancer compared with the general population.61,62 Therefore, some experts suggest offering counseling and screening to patients with hereditary pancreatitis beginning at 40 years of age. The most recommended screening methods are EUS, CT, and endoscopic retrograde cholangiopancreatography; there is no consensus on screening interval. Additionally, patients with chronic pancreatitis who exhibit a change in clinical symptoms (pain, weight loss, jaundice) should be evaluated for neoplasm.63 All patients at increased risk of cancer should be counseled on mitigating risk factors, especially alcohol and tobacco use.62,63 If a malignancy is suspected, a triphasic, pancreas protocol CT is the standard for diagnosis. If this test is not available or if the patient has an allergy to contrast media, MRI with gadolinium may be used.62
This article updates a previous article on this topic by Nair, et al.15
Data Sources: A PubMed search was completed in Clinical Queries using the key terms chronic pancreatitis and pancreatitis. The search included meta-analyses, randomized controlled trials, clinical trials, and reviews. Also searched were the Agency for Healthcare Research and Quality evidence reports, Clinical Evidence, the Cochrane database, the Institute for Clinical Systems Improvement, the National Guideline Clearinghouse database, Dynamed, and Essential Evidence Plus. Search dates: March 18, 2016, and September 20, 2017.
References
show all references1. Steer ML, Waxman I, Freedman S. Chronic pancreatitis. N Engl J Med. 1995;332(22):1482–1490....
2. Ahmed SA, Wray C, Rilo HL, et al. Chronic pancreatitis: recent advances and ongoing challenges. Curr Probl Surg. 2006;43(3):127–238.
3. Conwell DL, Lee LS, Yadav D, et al. American Pancreatic Association practice guidelines in chronic pancreatitis. Pancreas. 2014;43(8):1143–1162.
4. Etemad B, Whitcomb DC. Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology. 2001;120(3):682–707.
5. Conwell DL, Banks PA, Sandhu BS, et al. Validation of demographics, etiology, and risk factors for chronic pancreatitis in the USA: a report of the North American Pancreas Study (NAPS) Group. Dig Dis Sci. 2017;62(8):2133–2140.
6. Muniraj T, Aslanian HR, Farrell J, Jamidar PA. Chronic pancreatitis, a comprehensive review and update. Part I: epidemiology, etiology, risk factors, genetics, pathophysiology, and clinical features. Dis Mon. 2014;60(12):530–550.
7. Schneider A, Whitcomb DC. Hereditary pancreatitis: a model for inflammatory diseases of the pancreas. Best Pract Res Clin Gastroenterol. 2002;16(3):347–363.
8. Keiles S, Kammesheidt A. Identification of CFTR, PRSS1, and SPINK1 mutations in 381 patients with pancreatitis. Pancreas. 2006;33(3):221–227.
9. Finkelberg DL, Sahani D, Deshpande V, Brugge WR. Autoimmune pancreatitis. N Engl J Med. 2006;355(25):2670–2676.
10. Warshaw AL, Banks PA, Fernández-Del Castillo C. AGA technical review: treatment of pain in chronic pancreatitis. Gastroenterology. 1998;115(3):765–776.
11. Ammann RW, Muellhaupt B. The natural history of pain in alcoholic chronic pancreatitis. Gastroenterology. 1999;116(5):1132–1140.
12. Malka D, Hammel P, Sauvanet A, et al. Risk factors for diabetes mellitus in chronic pancreatitis. Gastroenterology. 2000;119(5):1324–1332.
13. Chen WX, Zhang WF, Li B, et al. Clinical manifestations of patients with chronic pancreatitis. Hepatobiliary Pancreat Dis Int. 2006;5(1):133–137.
14. Toskes PP, Hansell J, Cerda J, Deren JJ. Vitamin B 12 malabsorption in chronic pancreatic insufficiency. N Engl J Med. 1971;284(12):627–632.
15. Nair RJ, Lawler L, Miller MR. Chronic pancreatitis. Am Fam Physician. 2007;76(11):1679–1688.
16. Chase CW, Barker DE, Russell WL, Burns RP. Serum amylase and lipase in the evaluation of acute abdominal pain. Am Surg. 1996;62(12):1028–1033.
17. Seno T, Harada H, Ochi K, et al. Serum levels of six pancreatic enzymes as related to the degree of renal dysfunction. Am J Gastroenterol. 1995;90(11):2002–2005.
18. Munoz A, Katerndahl DA. Diagnosis and management of acute pancreatitis. Am Fam Physician. 2000;62(1):164–174.
19. Keim V, Teich N, Moessner J. Clinical value of a new fecal elastase test for detection of chronic pancreatitis. Clin Lab. 2003;49(5–6):209–215.
20. Somogyi L, Ross SO, Cintron M, Toskes PP. Comparison of biologic porcine secretin, synthetic porcine secretin, and synthetic human secretin in pancreatic function testing. Pancreas. 2003;27(3):230–234.
21. Ketwaroo G, Brown A, Young B, et al. Defining the accuracy of secretin pancreatic function testing in patients with suspected early chronic pancreatitis. Am J Gastroenterol. 2013;108(8):1360–1366.
22. Issa Y, Kempeneers MA, van Santvoort HC, Bollen TL, Bipat S, Boer-meester MA. Diagnostic performance of imaging modalities in chronic pancreatitis: a systematic review and meta-analysis. Eur Radiol. 2017;27(9):3820–3844.
23. Remer EM, Baker ME. Imaging of chronic pancreatitis. Radiol Clin North Am. 2002;40(6):1229–1242.
24. Lin Y, Tamakoshi A, Matsuno S, et al. Nationwide epidemiological survey of chronic pancreatitis in Japan. J Gastroenterol. 2000;35(2):136–141.
25. Adler DG, Baron TH, Davila RE, et al.; Standards of Practice Committee of American Society for Gastrointestinal Endoscopy. ASGE guideline: the role of ERCP in diseases of the biliary tract and the pancreas. Gastrointest Endosc. 2005;62(1):1–8.
26. Makary MA, Duncan MD, Harmon JW, et al. The role of magnetic resonance cholangiography in the management of patients with gallstone pancreatitis. Ann Surg. 2005;241(1):119–124.
27. Aronson N, Flamm CR, Mark D, et al. Endoscopic retrograde cholangiopancreatography. Evid Rep Technol Assess (Summ). 2002;(50):1–8.
28. Jacobson BC, Baron TH, Adler DG, et al.; American Society for Gastrointestinal Endoscopy. ASGE guideline: the role of endoscopy in the diagnosis and the management of cystic lesions and inflammatory fluid collections of the pancreas. Gastrointest Endosc. 2005;61(3):363–370.
29. Hollerbach S, Klamann A, Topalidis T, Schmiegel WH. Endoscopic ultrasonography (EUS) and fine-needle aspiration (FNA) cytology for diagnosis of chronic pancreatitis. Endoscopy. 2001;33(10):824–831.
30. Albashir S, Bronner MP, Parsi MA, Walsh RM, Stevens T. Endoscopic ultrasound, secretin endoscopic pancreatic function test, and histology: correlation in chronic pancreatitis. Am J Gastroenterol. 2010;105(11):2498–2503.
31. D'Haese JG, Ceyhan GO, Demir IE, Tieftrunk E, Friess H. Treatment options in painful chronic pancreatitis: a systematic review. HPB (Oxford). 2014;16(6):512–521.
32. van Esch AA, Wilder-Smith OH, Jansen JB, van Goor H, Drenth JP. Pharmacological management of pain in chronic pancreatitis. Dig Liver Dis. 2006;38(7):518–526.
33. Lowenfels AB, Maisonneuve P. Defining the role of smoking in chronic pancreatitis. Clin Gastroenterol Hepatol. 2011;9(3):196–197.
34. Pezzilli R, Morselli-Labate AM, Frulloni L, et al. The quality of life in patients with chronic pancreatitis evaluated using the SF-12 questionnaire: a comparative study with the SF-36 questionnaire. Dig Liver Dis. 2006;38(2):109–115.
35. Ahmed Ali U, Jens S, Busch OR, et al. Antioxidants for pain in chronic pancreatitis. Cochrane Database Syst Rev. 2014;(8):CD008945.
36. Gurusamy KS, Lusuku C, Davidson BR. Pregabalin for decreasing pancreatic pain in chronic pancreatitis. Cochrane Database Syst Rev. 2016;(2):CD011522.
37. Olesen SS, Bouwense SA, Wilder-Smith OH, van Goor H, Drewes AM. Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial. Gastroenterology. 2011;141(2):536–543.
38. Brown A, Hughes M, Tenner S, Banks PA. Does pancreatic enzyme supplementation reduce pain in patients with chronic pancreatitis: a meta-analysis. Am J Gastroenterol. 1997;92(11):2032–2035.
39. Czakó L, Takács T, Hegyi P, et al. Quality of life assessment after pancreatic enzyme replacement therapy in chronic pancreatitis. Can J Gastroenterol. 2003;17(10):597–603.
40. Domínguez-Muñoz JE, Iglesias-García J, Iglesias-Rey M, Figueiras A, Vilariño-Insua M. Effect of the administration schedule on the therapeutic efficacy of oral pancreatic enzyme supplements in patients with exocrine pancreatic insufficiency: a randomized, three-way crossover study [published correction appears in Aliment Pharmacol Ther. 2011; 34(10):1251–1253]. Aliment Pharmacol Ther. 2005;21(8):993–1000.
41. Safdi M, Bekal PK, Martin S, Saeed ZA, Burton F, Toskes PP. The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multi-center, placebo-controlled, parallel group trial in subjects with chronic pancreatitis [published correction appears in Pancreas. 2007;34(1):174]. Pancreas. 2006;33(2):156–162.
42. Shafiq N, Rana S, Bhasin D, et al. Pancreatic enzymes for chronic pancreatitis. Cochrane Database Syst Rev. 2009;(4):CD006302.
43. Rösch T, Daniel S, Scholz M, et al. Endoscopic treatment of chronic pancreatitis: a multicenter study of 1000 patients with long-term follow-up. Endoscopy. 2002;34(10):765–771.
44. Sharma SS, Bhargawa N, Govil A. Endoscopic management of pancreatic pseudocyst. Endoscopy. 2002;34(3):203–207.
45. Libera ED, Siqueira ES, Morais M, et al. Pancreatic pseudocysts transpapillary and transmural drainage. HPB Surg. 2000;11(5):333–338.
46. Froeschle G, Meyer-Pannwitt U, Brueckner M, Henne-Bruns D. A comparison between surgical, endoscopic and percutaneous management of pancreatic pseudocysts—long term results. Acta Chir Belg. 1993;93(3):102–106.
47. Morton JM, Brown A, Galanko JA, Norton JA, Grimm IS, Behrns KE. A national comparison of surgical versus percutaneous drainage of pancreatic pseudocysts: 1997–2001. J Gastrointest Surg. 2005;9(1):15–20.
48. Rosso E, Alexakis N, Ghaneh P, et al. Pancreatic pseudocyst in chronic pancreatitis: endoscopic and surgical treatment. Dig Surg. 2003;20(5):397–406.
49. Guda NM, Partington S, Freeman ML. Extracorporeal shock wave lithotripsy in the management of chronic calcific pancreatitis: a meta-analysis. JOP. 2005;6(1):6–12.
50. Dumonceau JM, Costamagna G, Tringali A, et al. Treatment for painful calcified chronic pancreatitis: extracorporeal shock wave lithotripsy versus endoscopic treatment: a randomised controlled trial. Gut. 2007;56(4):545–552.
51. van der Gaag NA, van Gulik TM, Busch OR, et al. Functional and medical outcomes after tailored surgery for pain due to chronic pancreatitis. Ann Surg. 2012;255(4):763–770.
52. Kalady MF, Broome AH, Meyers WC, Pappas TN. Immediate and long-term outcomes after lateral pancreaticojejunostomy for chronic pancreatitis. Am Surg. 2001;67(5):478–483.
53. Nealon WH, Matin S. Analysis of surgical success in preventing recurrent acute exacerbations in chronic pancreatitis. Ann Surg. 2001;233(6):793–800.
54. Cahen DL, Gouma DJ, Nio Y, et al. Endoscopic versus surgical drainage of the pancreatic duct in chronic pancreatitis. N Engl J Med. 2007;356(7):676–684.
55. Muniraj T, Aslanian HR, Farrell J, Jamidar PA. Chronic pancreatitis, a comprehensive review and update. Part II: diagnosis, complications, and management. Dis Mon. 2015;61(1):5–37.
56. Jimenez RE, Fernandez-del Castillo C, Rattner DW, Chang Y, Warshaw AL. Outcome of pancreaticoduodenectomy with pylorus preservation or with antrectomy in the treatment of chronic pancreatitis. Ann Surg. 2000;231(3):293–300.
57. Gurusamy KS, Lusuku C, Halkias C, Davidson BR. Duodenum-preserving pancreatic resection versus pancreaticoduodenectomy for chronic pancreatitis. Cochrane Database Syst Rev. 2016;(2):CD011521.
58. Zhao X, Cui N, Wang X, Cui Y. Surgical strategies in the treatment of chronic pancreatitis. Medicine (Baltimore). 2017;96(9):e6220.
59. Wahoff DC, Papalois BE, Najarian JS, et al. Autologous islet transplantation to prevent diabetes after pancreatic resection. Ann Surg. 1995;222(4):562–575.
60. Duggan SN, Smyth ND, Murphy A, Macnaughton D, O'Keefe SJ, Conlon KC. High prevalence of osteoporosis in patients with chronic pancreatitis. Clin Gastroenterol Hepatol. 2014;12(2):219–228.
61. Malka D, Hammel P, Maire F, et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut. 2002;51(6):849–852.
62. De La Cruz MS, Young AP, Ruffin MT. Diagnosis and management of pancreatic cancer. Am Fam Physician. 2014;89(8):626–632.
63. Ulrich CD. Pancreatic cancer in hereditary pancreatitis: consensus guidelines for prevention, screening and treatment. Pancreatology. 2001;1(5):416–422.
Copyright © 2018 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact
afpserv@aafp.org for copyright questions and/or permission requests.
- SHARE
Want to use this article elsewhere? Get Permissions
More in AFP
Editor's Collections
Related Content
More in Pubmed
MOST RECENT ISSUE
Email Alerts
Don't miss a single issue. Sign up for the free AFP email table of contents.
